License Agreements (Details Narrative) - USD ($) |
12 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|
May 17, 2022 |
Jun. 16, 2021 |
Oct. 06, 2020 |
Aug. 23, 2020 |
Aug. 19, 2020 |
Mar. 19, 2018 |
Dec. 31, 2022 |
Dec. 31, 2021 |
|
| Stock Issued During Period, Value, New Issues | $ 9,875,550 | |||||||
| CoNCERT Pharmaceuticals, Inc [Member] | License Rights [Member] | ||||||||
| Shares issued in connection with license agreement | 298,615 | |||||||
| Stock Issued During Period, Value, New Issues | $ 8,000,000 | |||||||
| Business Acquisition, Share Price | $ 26.79 | |||||||
| License Agreement [Member] | Elion Oncology [Member] | ||||||||
| Conditions for grant of license, description | The grant of license was conditioned on the following being satisfied by October 30, 2020: (i) our closing on an equity financing of at least $15 million in gross proceeds and (ii) successful up-listing to Nasdaq. | |||||||
| Cash paid under license agreement | $ 100,000 | |||||||
| Shares issued in connection with license agreement | 825,000 | 100,000 | 100,000 | |||||
| Common stock, lock-up description | Such shares were subject to a lock-up, with 50% of such shares released from such lock-up after six months and the remaining 25% tranches were released following 9 months and 12 months, respectively | |||||||
| Common Stock, Capital Shares Reserved for Future Issuance | 100,000 | |||||||
| Milestone payments, description | As additional consideration, we will pay Elion development and regulatory milestone payments (a portion of which are payable in shares of our common stock and a portion of which are payable in cash) upon the achievement of certain milestones, which include FDA or other regulatory approval and dosing a patient | |||||||
| Expense and related liability | $ 189,000 | |||||||
| Performance of milestone conditions, description | specific diligence milestones that consist of: (i) dosing a first patient in a Phase 1B clinical trial with a product within 12 months; and (ii) dosing a first patient with a product in a Phase 2 or 3 clinical trial within 48 months. Either party may terminate the agreement in the event of a material breach of the agreement that has not been cured following written notice and a 90-day opportunity to cure such breach (which is shortened to 15 days for a payment breach). | |||||||
| License Agreement [Member] | Elion Oncology [Member] | First Milestone [Member] | ||||||||
| Milestone payment description | shares of our common stock on each of the first and second anniversary dates of the Elion License Agreement, which we fulfilled on October 5, 2021 and 2022, respectively. | |||||||
| License Agreement [Member] | Ocuphire Pharma Inc [Member] | ||||||||
| Cash paid under license agreement | $ 200,000 | |||||||
| Shares issued in connection with license agreement | 44,689 | |||||||
| Liabilities assumed | $ 66,583 | |||||||
| License Agreement [Member] | Aposense, Ltd. [Member] | ||||||||
| Shares issued in connection with license agreement | 625,000 | |||||||
| Common stock, lock-up description | Such shares were subject to a lock-up, with 40% of such shares released from such lock-up after six months and the remaining two 30% tranches were released upon completion of the next two subsequent quarters | |||||||
| Milestone payments, description | As additional consideration, we will pay Aposense development and regulatory milestone payments (up to $3.0 million per milestone) upon the achievement of certain milestones, which primarily consist of having a drug indication approved by a regulatory authority in the United States or another country. In addition, we will pay Aposense one-time sales milestone payments based on the achievement during a calendar year of one or more thresholds for annual sales for products made and pay royalties based on annual licensing sales. We are also required to split any sales milestone payments or royalties we receive with Aposense based on any sub-license agreement we may enter into | |||||||
| License Agreement [Member] | Aposense, Ltd. [Member] | Maximum [Member] | ||||||||
| Development and regulatory milestone payments | $ 3,000,000.0 | |||||||
| License Agreement [Member] | Yuhan Corporation [Member] | ||||||||
| Shares issued in connection with license agreement | 500,000 | |||||||
| Milestone payments, description | In addition, we must pay Yuhan one-time sales milestone payments based on the achievement during a calendar year of one or more thresholds for annual sales for products made and pay royalties based on annual licensing sales. We are also required to split any milestone payments received with Yuhan based on any sub-license agreement we may enter into | |||||||
| Performance of milestone conditions, description | specific diligence milestones that consist of: (i) preparing a first draft of the product development plan within 90 days; (ii) requesting an FDA pre-IND meeting for a product within 6 months; (iii) dosing a first patient in a Phase 2A clinical trial with a product within 24 months; and (iv) dosing a first patient with a product in a Phase 2B clinical trial, Phase 3 clinical trial or other pivotal clinical trial with a product within 48 months | |||||||
| License Agreement [Member] | Yuhan Affiliate [Member] | Underwritten Public Offering [Member] | October 2020 [Member] | ||||||||
| Shares issued in connection with our 2020 offering | 750,000 | |||||||
| Proceeds from offering | $ 3,000,000 | |||||||